Pangea Laboratory Partners with Unilabs to Introduce Bladder CARE™ Assay in Switzerland, Advancing Non-Invasive Cancer Diagnostics Across Europe
Comunicato Precedente
Comunicato Successivo
"Through this strategic partnership with Pangea Laboratory, Unilabs reinforces its commitment to driving innovation in diagnostics, bringing Bladder CARE™ to Switzerland as a next-generation solution that empowers early detection and advances patient care," said Patrick Bornand, Head of Pathology, Genetics & Oncology at Unilabs Switzerland.
"Pangea Laboratory is committed to delivering non-invasive healthcare solutions that reduce patient burden while delivering highly accurate results. We are happy that the Unilabs team shares our vision, and the belief that Bladder CARE™ sets a new standard in the diagnosis of bladder cancer and UTUC," said Dr. Yap Ching Chew, COO of Pangea Laboratory.
About Pangea Laboratory
Founded in 2014, Pangea Laboratory is a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited diagnostics company dedicated to simplifying diagnosis for critical health conditions. For more information, visit https://pangealab.com/bladdercare/.
About Unilabs
Unilabs is a leading European provider of clinical laboratory testing and medical diagnostic imaging services, with over 109 laboratories and 44 imaging units across 12 countries. Headquartered in
Geneva, Unilabs performs over 106 million diagnostic tests and 1 million radiology exams annually, serving healthcare providers, governments, pharmaceutical companies, and the public. Unilabs focuses on swift, accurate diagnosis and aims to lead the shift from treatment to prediction and prevention, driven by advancements in molecular and genetic testing. For more information, visit
www.unilabs.com.
Contacts:
Pangea Laboratory
Abigail Kang, Marketing Manager
[email protected]
Unilabs Switzerland
Inês Camilo, Marketing Specialist
[email protected]
View original content:
